InflaRx N.V.

“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office

The European Medicines Agency is due to decide this week whether to recommend pan-EU marketing authorization for several products, including two treatments that are yet to be approved anywhere in the

The European Medicines Agency has recommended that pan-EU marketing authorization should be granted to eight new drugs, including Gohibic (vilobelimab) and Augtyro (repotrectinib), from InflaRx and Br

The developers of Coacillium, vilobelimab, avacincaptad pegol and temozolomide were this week due to provide the European Medicines Agency with oral explanations as to why their respective drugs, whic